CLINICAL THYROIDOLOGY FOR THE PUBLIC
A publication of the American Thyroid Association
Table of Contents
Welcome to Clinical Thyroidology for the Public. In this journal, we will bring to you the most up-to-date, cutting edge thyroid research. We will be providing summaries of research studies that were discussed in a recent issue of Clinical Thyroidology, a publication of the American Thyroid Association for physicians. These summaries are present in lay language to allow the rapid dissemination of thyroid research to the widest possible audience. This means that you are getting the latest information on thyroid research and treatment almost as soon as your physicians. As always, we are happy to entertain any suggestions to improve Clinical Thyroidology for the Public so let us know what you want to see.
We are also planning additional content, possibly some topic reviews, in future issues. As always, we are happy to entertain any suggestions to improve Clinical Thyroidology for the Public so let us know what you want to see.
We also provide even faster updates of late-breaking thyroid news through Twitter at @thyroidfriends and on Facebook. Our goal is to provide patients with the tools to be the most informed thyroid patient in the waiting room.
Also check out our friends in the Alliance for Thyroid Patient Education. The Alliance member groups consist of: the American Thyroid Association, the Graves’ Disease and Thyroid Foundation, the Light of Life Foundation, ThyCa: Thyroid Cancer Survivors Association, Thyroid Cancer Canada and Thyroid Federation International.
In this issue, the studies ask the following questions:
- How much Levothyroxine should be started for hypothyroidism during pregnancy?
- Is Graves’ disease always an autoimmune disorder?
- What causes thyrotoxic periodic paralysis?
- When thyroglobulin is undetectable, is any further testing needed in following patients with thyroid cancer?
- Are microRNAs a useful molecular marker for cancer in thyroid nodule biopsies?
- What is the significance the molecular marker RAS in papillary cancer?
We welcome your feedback and suggestions. Let us know what you want to see in this publication. I hope you find these summaries interesting and informative.
— Alan P. Farwell, MD